Posted by ABMN Staff on May 18th, 2024
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) had its price target cut by research analysts at Canaccord Genuity Group from $15.00 to $6.00 in a research note issued to investors on Thursday, Benzinga reports....
More of this article »